Key Points
-
Focal therapy is an emerging treatment option for low-risk and intermediate-risk prostate cancer
-
Owing to the multifocal nature of prostate cancer, careful patient selection for focal therapy is integral to treatment success: patients with unifocal cancer and those with an intermediate-risk index tumour and a surrounding low-grade secondary tumour might be suitable
-
Adequate preoperative assessment that includes prostate mapping is required to exclude high-grade disease before focal therapy
-
Focal therapy modalities include cryotherapy, high-intensity focused ultrasound, laser ablation, photodynamic therapy, irreversible electroporation, radiofrequency ablation and focal brachytherapy
-
Focal therapies are associated with improved postoperative preservation of sexual and urinary function compared with radical therapies
-
Additional data from large trials are required before the definitive role of focal therapies in prostate cancer can be determined
Abstract
Globally, the increased uptake of serum PSA level screening led to an increase in the number of diagnoses of low-risk and intermediate-risk prostate cancer. Traditionally, these patients have been considered for either active surveillance programmes or radical whole-gland therapies, such as prostatectomy or radiotherapy. Focal therapy is an emerging treatment option that involves the focal ablation of prostate cancer with preservation of surrounding healthy tissue. This approach might result in reduced morbidity when compared with whole-gland therapies. In current practice, much controversy surrounds optimal patient selection and preoperative tumour localization strategies. Focal therapy modalities include cryotherapy, high-intensity focused ultrasound, laser ablation, photodynamic therapy, irreversible electroporation, radiofrequency ablation and focal brachytherapy. However, as long-term oncological data for focal therapies are lacking, formal recommendations for its use cannot be made.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kim, S. P. et al. Contemporary national trends of prostate cancer screening among privately insured men in the United States. Urology http://dx.doi.org/10.1016/j.urology.2016.06.067 (2016).
Shoag, J. et al. Decline in prostate cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing. J. Urol. http://dx.doi.org/10.1016/j.juro.2016.03.171 (2016).
Stamey, T. A. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J. Urol. 172, 1297–1301 (2004).
Klotz, L. et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33, 272–277 (2014).
Wilt, T. J. et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203–213 (2012).
Klotz, L. et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33, 272–277 (2015).
Weerakoon, M. et al. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. BJU Int. 115, 50–56 (2015).
Sathianathen, N. J., Murphy, D. G., van den Bergh, R. C. & Lawrentschuk, N. Gleason pattern 4: active surveillance no more. BJU Int. 117, 856–857 (2015).
Lindner, U., Trachtenberg, J. & Lawrentschuk, N. Focal therapy in prostate cancer: modalities, findings and future considerations. Nat. Rev. Urol. 7, 562–571 (2010).
Ahmed, H. U. et al. Will focal therapy become a standard of care for men with localized prostate cancer? Nat. Clin. Pract. Oncol. 4, 632–642 (2007).
Donaldson, I. A. et al. Focal therapy: patients, interventions, and outcomes—a report from a consensus meeting. Eur. Urol. 67, 771–777 (2015).
Villers, A., McNeal, J. E., Freiha, F. S. & Stamey, T. A. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 70, 2313–2318 (1992).
Wise, A. M., Stamey, T. A., McNeal, J. E. & Clayton, J. L. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60, 264–269 (2002).
Djavan, B. et al. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech. Urol. 5, 139–142 (1999).
Mouraviev, V. et al. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110, 906–910 (2007).
Tareen, B. et al. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urology 73, 351–354; discussion 354–355 (2009).
Liu, W. et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Med. 15, 559–565 (2009).
Ahmed, H. U. The index lesion and the origin of prostate cancer. N. Engl. J. Med. 361, 1704–1706 (2009).
Algaba, F. & Montironi, R. Impact of prostate cancer multifocality on its biology and treatment. J. Endourol. 24, 799–804 (2010).
Lin, D. et al. Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor. Prostate 70, 1636–1644 (2010).
Stamey, T. A. et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71, 933–938 (1993).
Wolters, T. et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J. Urol. 185, 121–125 (2011).
Ohori, M. et al. Is focal therapy reasonable in patients with early stage prostate cancer (CaP)—an analysis of radical prostatectomy (RP) specimens. J. Urol. (Suppl.) 175, 507 Abstr. 1574 (2006).
Rukstalis, D. B., Goldknopf, J. L., Crowley, E. M. & Garcia, F. U. Prostate cryoablation: a scientific rationale for future modifications. Urology 60 (2 Suppl. 1), 19–25 (2002).
Tareen, B., G., Godoy, G. & Taneja, S. S. Focal therapy: a new paradigm for the treatment of prostate cancer. Rev. Urol. 11, 203–212 (2009).
Klotz, L. Active surveillance and focal therapy for low-intermediate risk prostate cancer. Translat. Androl. Urol. 4, 342–354 (2015).
Eggener, S. E. et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J. Urol. 178, 2260–2267 (2007).
Valerio, M. et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur. Urol. 66, 732–751 (2014).
Mohler, J. L. et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J. Natl. Compr. Canc. Netw. 10, 1081–1087 (2012).
Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649–655 (1982).
Thompson, I. et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177, 2106–2131 (2007).
Mian, B. M. et al. Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology 67, 379–383 (2006).
Polascik, T. J. et al. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate 68, 1380–1386 (2008).
Ong, W. L. et al. Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound-guided biopsy: the Victorian Transperineal Biopsy Collaboration experience. BJU Int. 116, 568–576 (2015).
Katelaris, N. C. et al. Current role of multiparametric magnetic resonance imaging in the management of prostate cancer. Korean J. Urol. 56, 337–345 (2015).
Crawford, E. D. et al. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate 73, 778–787 (2013).
Moore, C. M. et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur. Urol. 63, 125–140 (2013).
Singh, P. B. et al. Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. Eur. Urol. 66, 12–19 (2014).
Hu, Y. et al. MR to ultrasound registration for image-guided prostate interventions. Med. Image Anal. 16, 687–703 (2012).
Cornud, F. et al. Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? J. Urol. 191, 1272–1279 (2014).
Lindner, U., Lawrentschuk, N. & Trachtenberg, J. Image guidance for focal therapy of prostate cancer. World J. Urol. 28, 727–734 (2010).
Roach, M. 3rd et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int. J. Radiat. Oncol. Biol. Phys. 65, 965–974 (2006).
Nguyen, P. L. et al. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J. Urol. 188, 1151–1156 (2012).
Postema, A. W. et al. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J. Urol. http://dx.doi.org/10.1007/s00345-016-1782-x (2016).
Madersbacher, S., Pedevilla, M., Vingers, L., Susani, M. & Marberger, M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 55, 3346–3351 (1995).
Chopra, R. et al. MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology 265, 303–313 (2012).
Lindner, U. et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur. Urol. 57, 1111–1114 (2010).
Valerio, M. et al. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis. 17, 343–347 (2014).
van den Bos, W. et al. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. World J. Urol. 34, 657–664 (2016).
Zlotta, A. R. et al. Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br. J. Urol. 81, 265–275 (1998).
Lindner, U. et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J. Urol. 182, 1371–1377 (2009).
Arnott, J. On the Treatment of Cancer by the Regulated Application of an Anesthetic Temperature. 32–54 (J. Churchill, 1851).
Soanes, W. A. & Gonder, M. J. Use of cryosurgery in prostatic cancer. J. Urol. 99, 793–797 (1968).
Gonder, M. J., Soanes, W. A. & Shulman, S. Cryosurgical treatment of the prostate. Invest. Urol. 3, 372–378 (1966).
Marshall, S. & Taneja, S. Focal therapy for prostate cancer: the current status. Prostate Int. 3, 35–41 (2015).
Ward, J. F. & Jones, J. S. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 109, 1648–1654 (2012).
Ritch, C. R. & Katz, A. E. Prostate cryotherapy: current status. Curr. Opin. Urol. 19, 177–181 (2009).
Gowardhan, B. & Greene, D. Cryotherapy for the prostate: an in vitro and clinical study of two new developments; advanced cryoneedles and a temperature monitoring system. BJU Int. 100, 295–302 (2007).
Steed, J., Saliken, J. C., Donnelly, B. J. & Ali-Ridha, N. H. Correlation between thermosensor temperature and transrectal ultrasonography during prostate cryoablation. Can. Associ. Radiol. J. 48, 186–190 (1997).
Silverman, S. G. et al. MR imaging-guided percutaneous cryotherapy of liver tumors: initial experience. Radiology 217, 657–664 (2000).
Overduin, C. G. et al. T1-weighted MR image contrast around a cryoablation iceball: a phantom study and initial comparison with in vivo findings. Med. Phys. 41, 112301 (2014).
Tacke, J. et al. Imaging of interstitial cryotherapy — an in vitro comparison of ultrasound, computed tomography, and magnetic resonance imaging. Cryobiology 38, 250–259 (1999).
Barret, E. et al. Morbidity of focal therapy in the treatment of localized prostate cancer Eur. Urol. 63, 618–622 (2013).
Barqawi, A. B. et al. Targeted focal therapy for the management of organ confined prostate cancer. J. Urol. 192, 749–753 (2014).
Ellis, D. S., Manny, T. B. Jr & Rewcastle, J. C. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology. 70, 9–15 (2007).
Lambert, E. H., Bolte, K., Masson, P., & Katz, A. E. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology. 69, 1117–1120 (2007).
Onik, G., Vaughan, D., Lotenfoe, R., Dineen, M. & Brady, J. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol. Oncol. 26, 500–505 (2008).
Truesdale, M. D. et al. An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up. Cancer J. 16, 544–549 (2010).
Bahn, D. et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur. Urol. 62, 55–63 (2012).
Durand, M. et al. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int. 113, 56–64 (2014).
Guazzoni, G. Investigative study of the role of focal therapy for prostate cancer treatment. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT00928603 (2009).
Katz, A. E. Unilateral nerve-sparing cryoablation for low-risk, clinically localized, unilateral prostate cancer (POTENT-C). ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02459912 (2009).
Bianco, F. Fuse Image MRI Guided Prostate Cryotherapy (FIPC). ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02381990 (2015).
Mouraviev, V., Johansen, T. E. & Polascik, T. J. Contemporary results of focal therapy for prostate cancer using cryoablation. J. Endourol. 24, 827–834 (2010).
Shah, T. T. et al. Focal cryotherapy of localized prostate cancer: a systematic review of the literature. Expert Rev. Anticancer Ther. 14, 1337–1347 (2014).
Lynn, J. G., Zwemer, R. L. & Chick, A. J. The biological application of focused ultrasonic waves. Science 96, 119–120 (1942).
Copelan, A., Hartman, J., Chehab, M. & Venkatesan, A. M. High-intensity focused ultrasound: current status for image-guided therapy. Seminars Intervent. Radiol. 32, 398–415 (2015).
Hoogenboom, M. et al. Mechanical high-intensity focused ultrasound destruction of soft tissue: working mechanisms and physiologic effects. Ultrasound Med. Biol. 41, 1500–1517 (2015).
Hectors, S. J., Jacobs, I., Moonen, C. T., Strijkers, G. J. & Nicolay, K. MRI methods for the evaluation of high intensity focused ultrasound tumor treatment: current status and future needs. Magn. Reson. Med. 75, 302–317 (2016).
Napoli, A. et al. Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience. Eur. Urol. 63, 395–398 (2013).
Lukka, H. et al. High-intensity focused ultrasound for prostate cancer: a systematic review. Clin. Oncol. (R. Coll. Radiol.) 23, 117–127 (2011).
Ahmed, H. U. et al. Focal therapy for localized prostate cancer: a phase I/II trial. J. Urol. 185, 1246–1254 (2011).
Beerlage, H. P., Thuroff, S., Debruyne, F. M., Chaussy, C. & de la Rosette, J. J. Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology 54, 273–277 (1999).
Souchon, R. et al. Visualisation of HIFU lesions using elastography of the human prostate in vivo: preliminary results. Ultrasound Med. Biol. 29, 1007–1015 (2003).
Muto, S. et al. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn. J. Clin. Oncol. 38, 192–199 (2008).
Murat, F. J. et al. 854 Focal therapy of prostate cancer (PCA) with HIFU: influence on erectile dysfunction (ED). Eur. Urol. Supplements 8, 334 (2009).
El Fegoun, A. B. et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int. Braz. J. Urol. 37, 213–219 (2011).
Tay, K. J. et al. Initial experience with MRgFUS focal therapy for low-risk prostate cancer. J. Endourol. 25, A99–A100 (2011).
Dickinson, L. et al. A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: the INDEX study. Contemp. Clin. Trials 36, 68–80 (2013).
van Velthoven, R. et al. A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 19, 79–83 (2016).
Van Velthoven, R. et al. Primary zonal high intensity focused ultrasound for prostate cancer: results of a prospective phase iia feasibility study. Prostate Cancer 2014, 756189 (2014); erratum 2014, 640859 (2014).
Feijoo, E. R. et al. Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes. Eur. Urol. 69, 214–220 (2016).
Wenger, H., Yousuf, A., Oto, A. & Eggener, S. Laser ablation as focal therapy for prostate cancer. Curr. Opin. Urol. 24, 236–240 (2014).
Eymerit-Morin, C. et al. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer. Virchows Arch. 463, 547–552 (2013).
Raz, O. et al. Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur. Urol. 58, 173–177 (2010).
Schwarzmaier, H. J. et al. MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients. Eur. J. Radiol 59, 208–215 (2006).
Streitparth, F. et al. MR-guided laser ablation of osteoid osteoma in an open high-field system (1.0 T). Cardiovasc. Intervent. Radiol. 32, 320–325 (2009).
Lepor, H., Llukani, E., Sperling, D. & Futterer, J. J. Complications, recovery, and early functional outcomes and oncologic control following in-bore focal laser ablation of prostate cancer. Eur. Urol. 68, 924–926 (2015).
Oto, A. et al. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology 267, 932–940 (2013).
Natarajan, S. et al. Focal laser ablation of prostate cancer: phase I clinical trial. J. Urol. 196, 68–75 (2015).
Feller, J. Phase II laser focal therapy of prostate cancer (LITT or FLA). ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02243033 (2014).
Futterer, J. MR-guided focal laser ablation of the prostate. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02200809 (2014).
Trachtenberg, J. MRI targeted focal laser thermal therapy of prostate cancer (FLTT002). ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT01094665 (2010).
Woodrum, D. Focal laser ablation of prostate cancer tumors. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02600156 (2015).
Polnikorn, N. & Timpatanapong, P. Photochemotherapy of psoriasis. A review of mechanism and report of successful, treatment in pustular psoriasis. J. Med. Assoc. Thai. 60, 510–515 (1977).
Azzouzi, A. R., Lebdai, S., Benzaghou, F. & Stief, C. Vascular-targeted photodynamic therapy with TOOKAD Soluble in localized prostate cancer: standardization of the procedure. World J. Urol. 33, 937–944 (2015).
Azzouzi, A. R. et al. TOOKAD soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J. Urol. 33, 945–953 (2015).
Windahl, T., Andersson, S. O. & Lofgren, L. Photodynamic therapy of localised prostatic cancer. Lancet 336, 1139 (1990).
Trachtenberg, J. et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 102, 556–562 (2008).
Davidson, S. R. et al. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Phys. Med. Biol. 54, 2293–2313 (2009).
Huang, Z. et al. Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland. Lasers Surg. Med. 38, 672–681 (2006).
Azzouzi, A. R. et al. TOOKAD® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int. 112, 766–774 (2013).
Lebdai, S. et al. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® soluble focal treatment for localized prostate cancer. World J. Urol. 33, 965–971 (2015).
Pech, M. et al. Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc. Intervent. Radiol. 34, 132–138 (2011).
Martin, R. C. 2nd, McFarland, K., Ellis, S. & Velanovich, V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J. Am. Coll. Surg. 215, 361–369 (2012).
Charpentier, K. P. Irreversible electroporation for the ablation of liver tumors: are we there yet? Arch. Surg. 147, 1053–1061 (2012).
Rubinsky, J., Onik, G., Mikus, P. & Rubinsky, B. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J. Urol. 180, 2668–2674 (2008).
Niessen, C. et al. Percutaneous irreversible electroporation (IRE) of prostate cancer: contrast-enhanced ultrasound (CEUS) findings. Clin. Hemorheol. Microcirc. 61, 135–141 (2015).
Valerio, M. et al. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemporary Clin. Trials 39, 57–65 (2014).
Ting, F. et al. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis. 19, 46–52 (2016).
de la Rosette, J. Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT01835977 (2013).
Crook, J., Lukka, H., Klotz, L., Bestic, N. & Johnston, M. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ 164, 975–981 (2001).
Crook, J. M., Potters, L., Stock, R. G. & Zelefsky, M. J. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. Brachytherapy 4, 186–194 (2005).
Chao, M. W. et al. Brachytherapy: state-of-the-art radiotherapy in prostate cancer. BJU Int. 116, (Suppl. 3) 80–88 (2015).
Al-Qaisieh, B. et al. Dosimetry modeling for focal low-dose-rate prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 92, 787–793 (2015).
Cosset, J. M. et al. Focal brachytherapy for selected low-risk prostate cancers: a pilot study. Brachytherapy 12, 331–337 (2013).
Bachaud, J.-M. Phase II study of feasibility of focal therapy for prostate cancer of good prognosis with permanent i125 localized implant. (CURIEFOCALE). ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT01902680 (2013).
Morris, W. Focal therapy for prostate cancer - a pilot study of focal low dose rate brachytherapy (FTPC). ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT01830166 (2013).
Benoit, R. Prospective evaluation of focal brachytherapy using Cesium-131 for patients with low risk prostate cancer. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02290366 (2014).
Fernandezots, A. Hemiablative focal brachytherapy pilot study. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02643511 (2015).
Langley, S. Hemi-ablative prostate brachytherapy (HAPpy). ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02632669 (2015).
Hu, B., Hu, B., Chen, L., Li, J. & Huang, J. Contrast-enhanced ultrasonography evaluation of radiofrequency ablation of the prostate: a canine model. J. Endourol. 24, 89–93 (2010).
Richstone, L. et al. Ablation of bull prostate using novel bipolar radiofrequency ablation probe. J. Endourol. 23, 11–16 (2009).
Moore, C. M. et al. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. BJU Int. 116, 888–896 (2015).
Yap, T. et al. The effects of focal therapy for prostate cancer on sexual function: a combined analysis of three prospective trials. Eur. Urol. 69, 844–851 (2015).
Burnett, A. L. et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J. Urol. 178, 597–601 (2007).
Ramsay, C. R. et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Health Technol. Assess. 19, 1–490 (2015).
Eberli, D. Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound for the Treatment of Prostate Cancer. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02265159 (2015).
Bladou, F. Focal therapy using HIFU for localised prostate cancer. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02016040 (2013).
InSightec. Focal MR-guided focused ultrasound treatment of localized low-intermediate risk prostate cancer: feasibility study. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT01226576 (2016).
Emberton, M. Focal prostate radiofrequency ablation (ProRAFT). ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02294903 (2014).
PowSang, J. Focal prostate radio-frequency ablation. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02328807 (2014).
Machtay, M. Magnetic resonance guided focal stereotactic radiosurgery in treating patients with low- or intermediate-risk localized prostate cancer. ClinicalTrials.govhttps://clinicaltrials.gov/show/NCT02163317 (2014).
Author information
Authors and Affiliations
Contributions
M.P. and N.K. researched data for and wrote the article. U.L. and N.L. made substantial contributions to discussions of content and reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (figure)
Summary of search strategy. (PDF 109 kb)
Rights and permissions
About this article
Cite this article
Perera, M., Krishnananthan, N., Lindner, U. et al. An update on focal therapy for prostate cancer. Nat Rev Urol 13, 641–653 (2016). https://doi.org/10.1038/nrurol.2016.177
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.177
This article is cited by
-
A mitochondrion-targeted cyanine agent for NIR-II fluorescence-guided surgery combined with intraoperative photothermal therapy to reduce prostate cancer recurrence
Journal of Nanobiotechnology (2024)
-
A Review of Energy Modalities Used for Focal Therapy of Prostate Cancer
Current Surgery Reports (2023)
-
Real-Time and Delayed Imaging of Tissue and Effects of Prostate Tissue Ablation
Current Urology Reports (2023)
-
Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes
BMC Urology (2022)
-
Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE)
World Journal of Urology (2021)